Logo image of BOLT

BOLT BIOTHERAPEUTICS INC (BOLT) Stock Price, Quote, News and Overview

NASDAQ:BOLT - Nasdaq - US0977021049 - Common Stock - Currency: USD

0.3146  +0 (+0.19%)

After market: 0.319 +0 (+1.4%)

BOLT Quote, Performance and Key Statistics

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (5/30/2025, 8:00:01 PM)

After market: 0.319 +0 (+1.4%)

0.3146

+0 (+0.19%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High0.8
52 Week Low0.28
Market Cap12.06M
Shares38.34M
Float37.47M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-11 2025-08-11
IPO02-05 2021-02-05


BOLT short term performance overview.The bars show the price performance of BOLT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

BOLT long term performance overview.The bars show the price performance of BOLT in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BOLT is 0.3146 USD. In the past month the price decreased by -10.37%. In the past year, price decreased by -58.42%.

BOLT BIOTHERAPEUTICS INC / BOLT Daily stock chart

BOLT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 328.74B
AMGN AMGEN INC 13.88 154.96B
GILD GILEAD SCIENCES INC 14.22 136.93B
VRTX VERTEX PHARMACEUTICALS INC N/A 113.52B
REGN REGENERON PHARMACEUTICALS 11.06 52.94B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.71B
ARGX ARGENX SE - ADR 97.66 35.00B
ONC BEONE MEDICINES LTD-ADR 6.28 26.55B
BNTX BIONTECH SE-ADR N/A 23.03B
NTRA NATERA INC N/A 21.54B
BIIB BIOGEN INC 8.2 19.02B
UTHR UNITED THERAPEUTICS CORP 12.72 14.38B

About BOLT

Company Profile

BOLT logo image Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 52 full-time employees. The company went IPO on 2021-02-05. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The firm is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Company Info

BOLT BIOTHERAPEUTICS INC

900 Chesapeake Drive

Redwood City CALIFORNIA 94063 US

CEO: Randall C. Schatzman

Employees: 100

BOLT Company Website

BOLT Investor Relations

Phone: 16506659295

BOLT BIOTHERAPEUTICS INC / BOLT FAQ

What is the stock price of BOLT BIOTHERAPEUTICS INC today?

The current stock price of BOLT is 0.3146 USD. The price increased by 0.19% in the last trading session.


What is the ticker symbol for BOLT BIOTHERAPEUTICS INC stock?

The exchange symbol of BOLT BIOTHERAPEUTICS INC is BOLT and it is listed on the Nasdaq exchange.


On which exchange is BOLT stock listed?

BOLT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BOLT BIOTHERAPEUTICS INC stock?

9 analysts have analysed BOLT and the average price target is 1.15 USD. This implies a price increase of 264.75% is expected in the next year compared to the current price of 0.3146. Check the BOLT BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BOLT BIOTHERAPEUTICS INC worth?

BOLT BIOTHERAPEUTICS INC (BOLT) has a market capitalization of 12.06M USD. This makes BOLT a Nano Cap stock.


How many employees does BOLT BIOTHERAPEUTICS INC have?

BOLT BIOTHERAPEUTICS INC (BOLT) currently has 100 employees.


What are the support and resistance levels for BOLT BIOTHERAPEUTICS INC (BOLT) stock?

BOLT BIOTHERAPEUTICS INC (BOLT) has a resistance level at 0.32. Check the full technical report for a detailed analysis of BOLT support and resistance levels.


Is BOLT BIOTHERAPEUTICS INC (BOLT) expected to grow?

The Revenue of BOLT BIOTHERAPEUTICS INC (BOLT) is expected to decline by -63.83% in the next year. Check the estimates tab for more information on the BOLT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BOLT BIOTHERAPEUTICS INC (BOLT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BOLT BIOTHERAPEUTICS INC (BOLT) stock pay dividends?

BOLT does not pay a dividend.


When does BOLT BIOTHERAPEUTICS INC (BOLT) report earnings?

BOLT BIOTHERAPEUTICS INC (BOLT) will report earnings on 2025-08-11.


What is the Price/Earnings (PE) ratio of BOLT BIOTHERAPEUTICS INC (BOLT)?

BOLT BIOTHERAPEUTICS INC (BOLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).


What is the Short Interest ratio of BOLT BIOTHERAPEUTICS INC (BOLT) stock?

The outstanding short interest for BOLT BIOTHERAPEUTICS INC (BOLT) is 0.71% of its float. Check the ownership tab for more information on the BOLT short interest.


BOLT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BOLT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BOLT. While BOLT seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BOLT Financial Highlights

Over the last trailing twelve months BOLT reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 7.83% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -73.78%
ROE -135.33%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-3.57%
Sales Q2Q%-76.83%
EPS 1Y (TTM)7.83%
Revenue 1Y (TTM)-67.87%

BOLT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 49% to BOLT. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of 8.23% and a revenue growth -63.83% for BOLT


Ownership
Inst Owners48.23%
Ins Owners0.65%
Short Float %0.71%
Short Ratio2.11
Analysts
Analysts48.89
Price Target1.15 (265.54%)
EPS Next Y8.23%
Revenue Next Year-63.83%